Inflammation may help explain how GLP-1 drugs prevent AFib
New research presented at Heart Rhythm 2026 suggests taking GLP-1 receptor agonists (GLP-1-RAs) may reduce the risk of atrial fibrillation (AFib) and improve survival through mechanisms that extend beyond weight loss alone.
Kenneth Bilchick, MD, MS, director of electrophysiology research and a professor of cardiovascular medicine at the University of Virginia, presented those findings at the conference. He then spoke to Cardiovascular Business for a video interview.
Bilchick said GLP-1 drugs have an anti-inflammatory effect, which may what led to the lower AFib rates in GLP-1 patients.
The 13,034-patient study matched patients who initiated GLP-1-RA therapy to a similar cohort of more than 385,000 patients who had never received GLP-1-RA therapy and did not have a prior AFib diagnosis. Overall, the GLP-1 group had a significantly better survival rate and a lower risk of AFib. The researchers said this reduction in AFib risk remained consistent, regardless of the level of weight change. There was no difference in these benefits between patients who lost 10% or more of their body weight, less than 10%, and those who gained weight while taking GLP-1s.
Of the medications included in this study, the authors found semaglutide showed a stronger association with reduced AFib risk than liraglutide, dulaglutide and tirzepatide.
Bilchick said the data showed a reduction in new-onset AFib that persisted even after accounting for survival differences between groups. The findings point to a broader cardiometabolic and anti-inflammatory effect from the increasingly popular class of medications, which are commonly prescribed for diabetes, obesity and heart failure.
Lower inflammation from GLP-1s may prevent atrial fibrillation
“We know that the medications have benefits on glucose metabolism, but they also affect inflammation and fat metabolism,” he said.
One possible mechanism involves epicardial adipose tissue, the fat surrounding the heart that has been linked to inflammation and electrical remodeling associated with AFib. Bilchick said emerging evidence suggests GLP-1 therapies can reduce both the volume of this fat and the concentration of inflammatory saturated fatty acids within it.
“Inflammation in the fat that is around the heart can provoke myocardial changes, scar, electrical changes that lead to AFib,” he explained.
Although the study did not include molecular imaging or tissue analysis, Bilchick said the observation that AFib reduction occurred independently of weight loss supports the possibility of an inflammatory mechanism.
The growing attention on GLP-1 therapies comes alongside rapid advances in pulsed field ablation (PFA), one of the dominant procedural technologies discussed at Heart Rhythm 2026. Bilchick said the field is increasingly recognizing the importance of combining advanced procedures with therapies that target the underlying metabolic and inflammatory contributors to arrhythmias.
“We're now understanding that there's another component to it, that it's related to inflammation, it's related to metabolism,” he said.
Bilchick compared the trend to cardiology’s broader embrace of anti-inflammatory therapies for coronary artery disease, including the use of colchicine and other agents aimed at reducing vascular inflammation.
As AFib prevalence continues to rise with an aging population, Bilchick said combining state-of-the-art ablation technologies with therapies that address metabolic and inflammatory pathways might significantly improve long-term outcomes.
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: [email protected]